Company: MLTX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001821586-25-000018
Chunk: 98

Company: MoonLake Immunotherapeutics
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 98
---
 were $761 thousand and $725 thousand for the six months ended June 30, 2025 and 2024, respectively.The Company recorded the following lease and variable lease expenses for the three and six months ended June 30, 2025 and 2024: (in thousands)Three Months Ended June 30, 2025Three Months Ended June 30, 2024Six Months Ended June 30, 2025Six Months Ended June 30, 2024 Operating lease expense$366 $354 $730 $702 Variable lease expense12 — 23 — Total lease expense$378 $354 $753 $702 

Note 11 — Employee Benefit Plans 

The Company operates a defined benefit pension plan in Switzerland (the “Plan”) and a defined contribution pension plan in the United Kingdom, in accordance with local regulations and practices. As of June 30, 2025, the Plan covers the Company’s employees in Switzerland with benefits in the event of death, disability, retirement, or termination of employment. 

19

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025(Unaudited)

Components of Net Periodic Benefit Cost under the Plan(in thousands)Three Months Ended June 30, 2025Three Months Ended June 30, 2024Six Months Ended June 30, 2025Six Months Ended June 30, 2024Service cost$83$68$159$139Interest cost881617Expected return on plan assets(20)(15)(39)(30)Amortization of unrecognized loss3365Prior service credit recognized in current year(3)(2)(5)(5)Net periodic benefit cost$71$62$137$126The components of net periodic benefit cost other than the service cost component are included in general and administrative expense in the Company's condensed consolidated statements of operations and comprehensive loss.Employer Contributions under the PlanFor the six months ended June 30, 2025, contributions of $146 thousand (CHF 126 thousand) were made to the Plan. The Company presently anticipates contributing an additional estimated amount of $146 thousand (CHF 126 thousand) to fund the Plan in 2025 for a total of $292 thousand (CHF 252 thousand)

Note 12 — Shareholders’ Equity

Class A Ordinary Shares(1)Class C Ordinary Shares(1)